No Data
No Data
Larimar Stock Rallies 24% on FDA Removal of Partial Clinical Hold
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 42.86 percent increase over losses of
Design Therapeutics | 10-Q: Quarterly report